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event-free survival (freedom from reoperation, reinterven-
tion, and significant residual shunt) was as low as 48% in
a series of 24 patients.5 Common reasons for failure of this
demanding intervention are poor imaging and unsuitable
anatomy, such as crescent-shaped or multiple leaks and se-
vere calcification. Additional limitations result from inade-
quate device configuration, because the occluders in use
were originally designed for atrial and ventricular septal de-
fects or patent ducts. Consequently, surgery still remains the
criterion standard of treatment for paravalvular leaks while
the technology of interventional closure is being advanced.
Our program comprised 1842 heart valve surgeries in
2006, including 26 patients (0.14%) operated on for para-
valvular leaks. Even in this large series, the 3 cases presented
here are unusual because of the multiple previous surgeries.
These cases were technically challenging and of high risk,
and avoiding fourth-time cardiac surgery for reoperative
valve exchange by use of catheter-based intervention would
havebeenpreferable.We therefore advocate amultidisciplin-
ary approach that includes interventional cardiologists and
surgeons. Depending on level of hemolysis, severity of re-
gurgitation, and anatomy of the paravalvular leak, the risk
of surgery must be weighed against the likelihood of success
of intervention. Both treatment options are clearly explained
to the patient so that an informed decision can be made.
Surgical backup in case of interventional complications is
provided for every intervention as well. Future studies, per-
haps with more suitable device technology, may address a
hybrid approach, so that outcomes can be improved even
for most complex cases of paravalvular leakage.
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FIGURE 2. Interventional closure of paravalvular leak in patient 2. Two
occluder devices are correctly placed (arrows). AP, Aortic prosthesis.
Brief CommunicationsResection of a giant thoracic solitary fibrous tumor through two
separate thoracotomies
Chao-Kai Hu, MD,a Yih-Leong Chang, MD,b Wei-Cheng Lin, MD,a and Yung-Chie Lee, MD, PhD,a Taipei, TaiwanSolitary fibrous tumor (SFT) of the pleura is an uncommon
intrathoracic neoplasm. A middle-aged woman had progres-
sive exertional dyspnea for 6 months, and eventually respi-
ratory failure developed which necessitated ventilatory
From the Departments of Surgerya and Pathology,b National Taiwan University Hos-
pital and National Taiwan University College of Medicine, Taipei, Taiwan.
Received for publication Oct 10, 2007; revisions received Dec 18, 2007; accepted for
publication Dec 22, 2007.
Address for reprints: Yung-Chie Lee,MD, PhD,Department of Surgery, National Taiwan
University Hospital and National Taiwan University College of Medicine, No. 7,
Chung-Shan S Rd, Taipei, Taiwan 100 (E-mail: yclee@ntuh.gov.tw).
J Thorac Cardiovasc Surg 2008;136:1077-9
0022-5223/$34.00
Copyright  2008 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.12.015The Journal of Thoracic and Casupport. After examination, a giant tumor was found to oc-
cupy the whole left pleural cavity with chest wall distention
and severe mediastinal shift to the right side. We completely
resected this giant tumor by two separate thoracotomies. The
pathologic examination revealed an SFT weighing 5.1 kg.
Her respiratory condition improved markedly after the oper-
ation and she was discharged 23 days postoperatively.
CLINICAL SUMMARY
A 51-year-old woman, a nonsmoker, was referred to our
hospital with endotracheal intubation andmechanical ventila-
tion owing to respiratory distress caused by a huge lesion
occupying the left chest cavity. A large tumor had beenrdiovascular Surgery c Volume 136, Number 4 1077
Brief CommunicationsFIGURE 1. A, Initial chest radiography showed complete whiteout of the left thoracic cavity. B, Initial computed tomogram with contrast revealed one mild
heterogeneous, well-defined mass that compressed the mediastinum to right side.discovered in the left side of the chest 3 years earlier during
a physical examination, but she had ignored it because it
was asymptomatic. Sixmonths before admission, she had ex-
ertional dyspnea that she had treated with oxygen therapy
without seeking medical intervention. Seventeen days before
referral, the sudden onset of progressive dyspnea, drowsy
consciousness, generalized edema, and eventually a faint oc-
curred at home. She was sent to a district general hospital im-
mediately, where emergency intubation was performed.
On physical examination, bilateral decreased breath
sounds were noted without finger clubbing. Laboratory ex-
amination data were all within normal ranges, including
a fasting sugar level of 107 mg/dL. Chest radiography (Fig-
ure 1, A) and computed tomography (CT) (Figure 1, B) both
revealed one huge tumor that occupied the whole left chest
cavity with chest wall distention and shifting of the medias-
tinum to the right side. Echo-guided biopsy favored an SFT.
After referral to our hospital, an entirely en bloc tumor ex-
cision was done by two thoracotomies through the fifth and
ninth intercostal spaces. First, we made an incision through
the fifth intercostal space for the upper and middle parts of1078 The Journal of Thoracic and Cardiovascular Sutumor dissection. Because the huge tumor measuring 32 3
21 3 8 cm extended from the left apex downward to the
level of left kidney with downward compression of the dia-
phragm and complete atelectasis of the left lung, we added
an incision through the ninth intercostal space to dissect
the lower part of the tumor. Finally the tumor was taken as
a whole through the fifth intercostal space. The diaphragm
was preserved but became rather redundant. The lung could
be re-expanded but was diffusely congested owing to re-ex-
pansion lung edema. After complete resection, the tumor
weighed 5.1 kg with focal necrosis (Figure 2, A). Micro-
scopic examination disclosed a typical patternless pattern
with occasional mitosis (4/30 high-power fields) (Figure 2,
B). With the positive immunoreactivity of CD-34 and vi-
mentin, it was confirmed as an SFTwith malignant potential.
On the 23rd day after surgery, she was discharged in excel-
lent condition without sequel. During follow-up, thalido-
mide was prescribed for prevention of recurrence.
Seventeen months after the operation, there was no evidence
of local recurrence on chest radiograph (Figure 3). She was
well without any respiratory symptoms.FIGURE 2. A, The giant SFT was well circumscribed, white, and firm, with a whorled appearance and focal necrosis on cut surface. B, The tumor typ-
ically exhibited a patternless architecture characterized by the coexistence of hypocellular and hypercellular areas. (Hematoxylin and eosin; original mag-
nification 333.)rgery c October 2008
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SFTs were first described by Klemperer and Rabin1 in
1931. The growths were initially termed localized mesothe-
lioma because the tumor was believed to arise frommesothe-
lial cells.2 However, according to immunohistochemical
analysis, SFTs of the pleura express vimentin and CD-34,
which are markers of mesenchymal cells, and do not express
cytoplasmic keratins, which are found in mesotheliomas, in-
dicating that these fibromas originate from the mesenchyme
rather than from mesothelial cells.3
SFTs represent less than 5% of all neoplasms involving
the pleura. Two thirds of these tumors arise from the visceral
pleura, and one third arises from the parietal pleura.4 The eti-
ology of SFTs is still unknown. The most frequent symp-
toms are dyspnea, cough, and chest pain. Paraneoplastic
manifestations include arthritic pain, clubbed fingers, and
hypoglycemia, but about 54% of the patients are asymptom-
atic. The tumors are noted by chest x-ray screening. By the
time the tumors are found, their size can vary from centime-
ters to occupying the whole lung field. The SFTs on chest
radiograph vary from a sharply delineated round or lobu-
lated mass, with or without pleural effusion, to opacification
of the complete hemithorax. Computed tomographic scan-
ning and magnetic resonance imaging are important to eval-
uate the relationship of the tumor to neighboring structures
FIGURE 3. Follow-up chest radiograph 17 months after the operation
showed no evidence of recurrence or lung metastasis.The Journal of Thoracic and Cand to evaluate the resectability of the tumor. Displacement
rather than invasion of adjacent structures is a characteristic
finding of SFTs on computed tomography or magnetic res-
onance imaging.5
Histologic and immunohistochemical analysis are the
most important diagnostic measures. Surgical resection is
needed. Fine needle aspiration is mostly inconclusive be-
cause of the combination of acellular and hypercellular
portions. The microscopic picture is dominated by a
‘‘patternless pattern,’’ with fibroblasts, collagen, and reticu-
lar fibers haphazardly arranged. Immunohistochemical
study shows immunoreactivity for vimentin and CD-34. En-
gland, Hochholzer, and McCarthy6 listed criteria of malig-
nant SFTs as followed: 4 mitotic figures in 10 high-power
fields, hemorrhage, high cellularity, pleomorphism, and
necrosis.
Most of these tumors have a benign clinical course if
resected completely. However, according to the literature,
even after complete resection, benign SFT still can result
in local recurrence, malignant transformation, distant me-
tastasis, and even death. On the contrary, even if the path-
ologic diagnosis is malignant SFT, cure may be effected
by wide local resection. Because SFTs have the potential
for adverse biological behavior, such as repeated recur-
rences or malignant transformation, the principle of treat-
ing this tumor is complete resection and followed by
long-term follow-up.3
Oral thalidomide was prescribed because of our previous
successful experience with thalidomide as an adjuvant
therapy for patients with malignant SFT, margin-involved
desmoids, and unresectable metastatic osteosarcoma.
Thalidomide is postulated to have antiangiogenic activity
through its ability to interfere with the vascular endothelial
growth factor and basic fibroblast growth factor pathway.7
In summary, our patient had an exceptionally huge SFT
weighing 5.1 kg that occupied the whole left thoracic cavity.
To our knowledge, it is the biggest one ever reported in the
literature. Thalidomide was prescribed for 9 months after the
operation. There has been no recurrence or any sequel during
17 months’ follow-up.
References
1. Klemperer P, Rabin CB. Primary neoplasms of the pleura. Arch Pathol. 1931;11:
385-412.
2. Jha V, Gil J, Teirstein AS. Familial solitary fibrous tumor of the pleura. A case re-
port. Chest. 2005;127:1852-4.
3. Chang YL, Lee YC, Wu CT. Thoracic solitary fibrous tumour: clinical and patho-
logical diversity. Lung Cancer. 1999;23:53-60.
4. Rena O, Filosso PL, Papalia E, Molinatti M, Marzio PD, Maggi G, et al. Solitary
fibrous tumour of the pleura: surgical treatment. Eur Cardiothorac Surg. 2001;
19:185-9.
5. Sandvliet RH, Heysteeg M, Paul MA. A large thoracic mass in a 57-year-old pa-
tient. Chest. 2000;117:897-900.
6. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fi-
brous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg
Pathol. 1989;13:640-58.
7. Tsai YC, Wu CT, Hong RL. Response of refractory osteosarcoma to thalidomide
and celecoxib. Lancet Oncol. 2005;6:997-9.ardiovascular Surgery c Volume 136, Number 4 1079
